The Director General of the Agence nationale de sécurité du médicament et des produits de santé shall inform without delay of any incident or risk of incident defined in Article L. 5212-2:
the Etablissement Français du Sang (French Blood Establishment), with regard to medical devices used in the collection, manufacture and administration of blood-derived products;
-the Agence de la biomédecine, for medical devices used in the collection, processing, preservation and use of human organs, tissues and cells.
The Director General of the Agency regularly informs the above-mentioned bodies of other incidents or malfunctions in relation to their missions and responsibilities.
He shall inform the European Commission and the Member States of the European Union or parties to the Agreement on the European Economic Area of the measures he has taken or intends to take to put an end to incidents or risks of incidents or to prevent their recurrence, and of the incidents which made them necessary.